Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 986-993

  Ueno, Naoto T ^a   Rondón, Gabriela ^a   Mirza, Nadeem Q ^a   Geisler, Deborah K ^a   Anderlini, Paolo ^a   Giralt, Sergio A ^a   Andersson, Borje S ^a   Claxton, David F ^a   Gajewski, James L ^a   Khouri, Issa F ^a   Körbling, Martin ^a   Mehra, Rakesh C ^a   Przepiorka, Donna ^a   Rahman, Zia ^a   Samuels, Barry I ^a   Van Besien, Koen ^a   Hortobagyi, Gabriel N ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; THIOTEPA;

ADULT; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER METASTASIS; METASTASIS; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 0031911005     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.986     Document Type: Article

References (45)

1. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
2. Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207-1216, 1990
3. Dunphy FR, Spitzer G, Fornoff JE, et al: Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 73:2157-2167, 1994
4. Ayash LJ, Wheeler C, Fairclough D, et al: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13:2043-2049, 1995
5. Kennedy MJ, Beveridge RA, Rowley SD, et al: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920-926, 1991
6. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383, 1994
7. Fields KK, Elfenbein GJ, Trudeau WL, et al: Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous transplantation. J Clin Oncol 14:1868-1876, 1996
8. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268, 1995
9. Giralt S, Hester J, Huh Y, et al: CDS-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337-4343, 1995
10. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-2050, 1995
11. Kumar L: Donor leucocyte infusions for relapse in chronic myelogenous leukaemia. Lancet 344:1101-1102, 1994
12. Porter DL, Roth MS, McGarigle C, et al: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100-106, 1994
13. Mehta J: Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma 10:427-432, 1993
14. Drobyski WR, Keever CA, Roth MS, et al: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310-2318, 1993
15. Bar BM, Schattenberg A, Mensink EJ, et al: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 11:513-519, 1993
16. Brenner MK, Heslop HE: Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol 4:727-749, 1991
17. van Besien KW, Mehra RC, Giralt SA, et al: Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity and survival depend on disease histology. Am J Med 100:299-307, 1996
18. van Besien KW, Khouri IF, Giralt SA, et al: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol 13:1096-1102, 1995
19. Jones RJ, Ambinder RF, Piantadosi S, et al: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649-653, 1991
20. Mazumder A, Grimm EA, Zhang HZ, et al: Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res 42:913-918, 1982
21. Rayner AA, Grimm EA, Lotze MT, et al: Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 75:67-75, 1985
22. Grimm EA, Wilson DJ: The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol 94:568-578, 1985
23. Jerome KR, Barnd DL, Bendt KM, et al: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51:2908-2916, 1991
24. Celis E, Tsai V, Crimi C, et al: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105-2109, 1994
25. Baxevanis CN, Dedoussis GV, Papadopoulos NG, et al: Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74:1275-1282, 1994
26. Linehan DC, Goedegebuure PS, Peoples GE, et al: Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155:4486-4491, 1995
27. Chakravarty PK, Sinha DK: Inhibition of mammary tumorigenesis in virgin rats by adoptive transfer of splenocytes from parous donors. Cancer Immunol Immunother 33:263-266, 1991
28. Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 6:839-853, 1988
29. Paciucci PA, Holland JF, Glidewell O, et al: Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer. J Clin Oncol 7:869-878, 1989
30. Kennedy MJ, Vogelsang GB, Beveridge RA, et al: Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11:478-484, 1993
31. Kennedy MJ, Vogelsang GB, Jones RJ, et al: Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249-257, 1994
32. Forman SJ, Blume KG, Krance RA, et al: A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: Methotrexate/prednisone v cyclosporine A/prednisone. Transplant Proc 19:2605-2607, 1987
33. Przepiorka D, Ippoliti C, Khouri I, et al: Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 88:4383-4389, 1996
34. Przepiorka D, Ippoliti C, Panina A, et al: Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 13:461-464, 1994
35. Goodrich JM, Bowden RA, Fisher L, et al: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173-178, 1993
36. Masur H: Prevention and treatment of pneumocystis pneumonia. N Engl J Med 327:1853-1860, 1992 [published erratum appears in N Engl J Med 328:1136, 1993]
37. Przepiorka D, Selvaggi K, Rosenzweig PQ, et al: Aerosolized pentamidine for prevention of Pneumocystis pneumonia after allogeneic marrow transplantation. Bone Marrow Transplant 7:324-325, 1991
38. Winston DJ, Ho WG, Bartoni K, et al: Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 12:283-288, 1993
39. Bearman SI, Appelbaum FR, Buckner CD, et al: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1988
40. Yam PY, Petz LD, Knowlton RG, et al: Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 43:399-407, 1987
41. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295-304, 1974
42. Atkinson K, Horowitz MM, Gale RP, et al: Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459-2464, 1990
43. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
44. Eibl B, Schwaighofer H, Nachbaur D, et al: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501-1508, 1996
45. Bonini C, Verzeletti S, Traversari C, et al: A pilot study of HSV-TK gene transfer into donor peripheral blood lymphocytes for controlled GVL after allo-BMT. Blood 88:487a, 1996 (suppl 1, abstr 1936)